Both drugs have proven to be effective in reducing inflammation through various pathways: they reduced CRP levels in patients with obesity, while colchicine was also effective in reducing IL‐6, IL‐16, resistin, complement proteins C5a and C9, and the activity of the COX‐2 enzyme.40, 47. Here, IL16 is linked to obesity due to melanocortin 4 receptor deficiency.